Chongqing Claruvis initiates study on YY001 for glabellar lines
A multi-center, open-label study is underway to assess the efficacy and safety of YY001, a recombinant botulinum toxin type A.
Asset / Drug
Drug and asset intelligence for YY001 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.